INNOCARE
诺诚健华

InnoCare Pharma – 2021 Annual Results

March 2022

Disclaimer

These materials are for information purposes only and do not constitute or form part of an offer or invitation to sell or issue or the solicitation of an offer or invitation to buy or subscribe for securities of InnoCare Pharma Limited (the "Company") or any of its holding company or subsidiaries in any jurisdiction. No part of these materials shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.

The information or opinions contained in these materials has not been independently verified. No representation or warranty, whether expressed or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information and opinions contained in these materials are provided as of the date of the presentation, are subject to change without notice and will not be updated or otherwise revised to reflect any developments, which may occur after the date of the presentation. The Company, any of its affiliates, directors, supervisors, senior managers, officers, employees, advisers and their respective representatives shall not have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from or in reliance upon any information contained or presented in or derived from these materials or otherwise arising in connection with these materials.

These materials contain statements that reflect the Company's current beliefs and expectations about the future as of the respective dates indicated herein. These forward-looking statements are based on a number of assumptions about the Company's operations and businesses and on factors beyond the Company's control, and are subject to significant risks and uncertainties, and, accordingly, the actual results may differ materially from these forward-looking statements. You should not place undue reliance on any of such forward-looking information. The Company assumes no obligation to update or otherwise revise these forward-looking statements for new information, events or circumstances that emerge subsequent to such dates.

Our Vision

To Become
a **Global Biopharmaceutical Leader**
that Develops and Delivers
Innovative Therapies for Patients **Worldwide**

Oncology   **Autoimmune**

Our Therapeutic Focus

InnoCare Investment Highlights

INNOCARE
诺诚健华

1 Top-tier Founder & Management Team

✓ Experienced founders and strong management team with an excellent track record in drug discovery, clinical development, business development and commercialization

2 Fully-integrated Drug Innovation Platform

✓ In-house drug discovery technology platform and highly efficient clinical development team
✓ Well established sales force and novel drug manufacturing facilities

3 A Leading Hema-oncology Franchise

✓ Orelabrutinib launched in 2021, NRDL inclusion to drive accelerated penetration from 2022 and beyond
✓ Differentiated approach to hard-to-treat B-cell lymphomas with Tafasitamab, E-3 Ligase, CD20xCD3 molecules, BCL-2
✓ Focused and effective sales force in China

4 Autoimmune Diseases Drugs Covering Both B cell and T cell Pathogenic Pathways

✓ Orelabrutinib - Partnered with Biogen in MS; finished Phase II in SLE with positive results
✓ ICP-332 – Potential Best-in-class TYK-2 inhibitor, entering Phase II in multiple indications
✓ Several compounds targeting different pathways offering a comprehensive coverage of autoimmune disease

5 Competitive Solid Tumor Portfolio

✓ Highly selective FGFR, TRK and SHP2 inhibitors in Phase I or II clinical studies in both China and U.S.
✓ Advanced solid tumor pipeline covering multiple promising targets i.e. potential first-in-class CCR8, bispecific antibodies

6 Strong Cash Position Providing Safety and Flexibility

✓ Continue expansion of portfolio through internal and external opportunities
✓ M&A opportunities for assets and platforms

Stellar Achievements in 2021

Successful Launch of Orelabrutinib

- Orelabrutinib achieved gross sales of **RMB241.1 million** in 2021
- **Successful NRDL inclusion**
- Rapid Market Penetration
- Commercial team expansion completed

Monumental BD Accomplishments

- **Out-licensing**: Orelabrutinib in MS to Biogen
- **In-licensing**: Tafasitamab in hematology and oncology from Incyte
- **Collaboration** with KeyMed

Rapidly Maturing Pipeline

- Promising results from Orelabrutinib **Phase II SLE trial**
- **MS global Phase II trial ongoing**
- **Promising Phase I data from ICP-332**
- Preliminary data assuring efficacy for **ICP-192** and **ICP-723**
- Differentiated strategy to DLBCL well defined
- **5** in-house developed NMEs disclosed
- **30+** ongoing clinical trials

Expanding Infrastructure and Talent Team

- Commercial production of Orelabrutinib in Guangzhou facility at the finish-line
- Biological drug R&D and production facility in Beijing
- Key positions filled (CMO, COO, General Counsel, Biology VP, and etc.)
- Staff expanded to **800+**

Solid Financial Position

- Over **RMB1 billion** revenue in 2021
- Over **RMB5 billion** net cash in hand
- Cost sensitive and cost efficient culture

Commercialization Update

Strong Uptake of Core Product - Orelabrutinib

宜诺凯

- **Indications:**
  - R/R Mantle Cell Lymphoma ("MCL")
  - R/R Chronic Lymphocytic Leukemia/Small Cell leukemia ("CLL/SLL")
- **Records Setting:**
  - From FPI to NDA filing: 1.5 years
  - From FPI to NDA approval: 2.5 years

1st Year Commercialization

- Gross revenue reached **RMB241.1M** in 2021
- An experienced in-house team effectively penetrated the market:
  - Penetrated **260+** Cities
  - Covered **1,000+** Hospitals
  - Educated **5,000+** Doctors
- **Successfully included in NRDL**
- Recommended use by **CSCO Diagnosis and Treatment Guidelines** for r/r CLL/SLL, r/r MCL, r/r DLBCL and PCNSL
- Well prepared for post-NRDL era sales ramp up:
  - Sales and marketing team **~ 250**
  - Hospital entry (进院) process moving smoothly
  - Implementation of NRDL progressing swiftly

Business Development Update

Out-licensed Orelabrutinib in MS with Biogen and In-licensed Tafasitamab

A BTKi with BBB Penetration Capability for the Potential Treatment of MS

INNOCARE  Biogen

Out-license

- **Biogen obtained MS worldwide rights** and **certain autoimmune disease rights outside China**
- InnoCare retained oncology worldwide rights and certain autoimmune disease rights in Greater China
- Upfront Payment of **US$125M Received**
- **Potential to receive milestone US$812.5M** and mid teens royalty
- A jump-start step to globalization, validation of Orelabrutinib's safety profile, and demonstration of R&D and BD capabilities

Status

- **Global Phase II MS trial ongoing**

Tafasitamab - A differentiated CD-19 Antibody for r/r DLBCL

INNOCARE  Incyte

In-license

- InnoCare obtained **exclusive worldwide rights in Greater China**
- MONJUVI (Tafasitamab-cxix) in combination with lenalidomide is **the first and only FDA-approved treatment for 2nd line DLBCL**, and also approved in Europe
- In Phase III studies for 1L DLBCL, r/r FL and more by Incyte/MorphoSys
- Solidified our long-term strategy of developing a leading hema-oncology franchise

Status

- **Imminent launch in BoAo, Hainan**
- **IND for bridging trial was accepted by CDE**

1 Clinical Update

Orelabrutinib (ICP-022) : Promising results from SLE Phase II trial

- Safety re-assured and promising efficacy observed
- The **only BTKi** ever **shown efficacy** in Phase II SLE trials
- Potentially the **first-in-class BTKi in SLE**
- Further development in SLE warranted and planned

SRI-4 response rate at 12 weeks



- The Phase II trial evaluated the safety and efficacy of Orelabrutinib in patients with mild to moderate SLE
- Orelabrutinib **was safe and well tolerated** at all doses
- **SLE Responder Index ("SRI")-4 response rates increased in a dose dependent manner**
- A reduction in levels of proteinuria, and improvement of immunologic markers, including reduced immunoglobulin G and increased complements C3 and C4 were observed

Clinical Update

ICP-332: Impeccable Phase I results

- **Phase I study**: SAD (5 ~ 320 mg) and MAD (40 ~ 160 mg QD) for 14 days
- Demonstrated **dose proportionality of the PK parameters** in the range of 5 mg ~ 320 mg
- **Safe and well tolerated, no significant decrease of platelet and hemoglobin**
- No drug accumulation and no significant food effect observed
- Phase II study is underway

Phase I MAD results

First-Patient-In (FPI) in Aug 2021
Enrollment finished in Jan 2022



Avoided JAK2-related AE



C_{av}, average plasma concentration; **IC_{50}**, half-maximal inhibition concentration; **LLN**, lower limits of normal; **IL-12**, interleukin-12; **IFNα**, interferon α.

3 Clinical Update

ICP-192: Promising safety and efficacy seen in Phase II trials

In China

- **Finished dose-escalation ranging from 2mg to 26mg** (10 dosage groups) and **no DLT observed**
- Safe and well-tolerated in patients with advanced solid tumors
- **20mg** Gunagratinib showed **preliminary efficacy in cholangiocarcinoma patients** with **60.0% ORR** and **100% DCR**
- Anti-tumor activity of Gunagratinib was demonstrated in **head & neck cancer** patients carrying **FGF/FGFR gene aberrations** with an **ORR of 33.3%**
- Progressing Phase II trials for advanced cholangiocarcinoma, head &neck cancer and urothelial cancer

One of the **most advanced pan-FGFR inhibitors** under clinical development in China

In the U.S. / Australia

- **Phase I/II trial** with dose escalation in advanced solid tumors and dose expansion in **cholangiocarcinoma and head & neck cancer ongoing**
- Granted as **Orphan Drug Designation ("ODD") by FDA** for cholangiocarcinoma in June 2021

4 Clinical Update

ICP-723: Promising safety and efficacy seen in Phase I trial

- **New generation of TRK inhibitor**
- Phase I dose escalation: safe and well tolerated in solid tumor patients and **no DLTs observed** in 6 dosage groups (1-8 mg)
- **ORR 80% (4 PR in 5 patients) with various cancers carrying NTRK fusion**
- Initiating Phase I trial in the U.S. in 2022

Distribution and frequency of *NTRK* fusions in adult[1]



Pre-clinical Results



NTRKs Mutations

	TRKA	TRKB	TRKC
Solvent front	G595R	G639R	G623R/E
Gatekeeper	F589L	F633L	F617L
xDFG	G667C/A/S	G709C	G696C/A

ICP-723 shows excellent activities against TRK resistance mutations including gatekeeper, xDFG and solvent front mutations.

[1] *NTRK* fusion-positive cancers and TRK inhibitor therapy *Emiliano Cocco, Maurizio Scaltriti and Alexander Drilon*

5 Clinical Update

Differentiated strategy to DLBCL well defined

- **MCD subtype DLBCL identified as a subgroup with potential high sensitivity to BTKis**
  - **MCD subgroup** is predominantly enriched with B-cell receptor-dependent NF-κB activation which indicates this patient sub-group might respond well to BTK inhibitors
- **Orelabrutinib may be a superior BTKi when combined with other antibody drugs**
  - The preclinical model proved that **Orelabrutinib preserves NK-cell-mediated antibody-dependent cell-mediated cytotoxicity ("ADCC") induced by anti-CD20 antibody due to less inducible T cell kinase ("ITK") inhibition**
- A comprehensive tool-kit including Orelabrutinib, Tafasitamab, ICP-B02 and ICP-490 offers us a unique position to tackle all stages of DLBCL patients with combination therapies



Research and & Development

Product Pipeline – Liquid Cancer



Research and & Development

Product Pipeline – Solid Tumors and Autoimmune Diseases

2022 Milestones & Catalysts – A Busy and Eventful Period

Liquid Cancer	■ **Orelabrutinib** ❑ r/r WM NDA accepted in 1Q2022 ❑ Submit r/r MZL NDA in mid-2022 ❑ Complete patient enrollment for r/r MCL in U.S. in 2022	■ **Tafasitamab** ❑ 1st prescription in 1H2022 ❑ Submission in Macau/HK/Big Bay Area in 2022 ❑ Initiate registrational trial in Mainland China in 2022	■ **CD3/CD20 -** PoC in 2022 ■ **Explore multiple combo therapies** ■ **Submit IND for 2 more NMEs in 2022**
Solid Tumors	■ **ICP-192** ❑ Initiate iCCA registrational trial ❑ PoC for Head & Neck trial ❑ Complete Phase I clinical study in U.S./Global	■ **ICP-723** ❑ Start a NTRK mutation-based registrational trial ❑ Initiate patient enrollment in U.S.	■ **1-2 new molecules into clinical expansion** ■ **2-3 NMEs into Phase I**
Auto-immune Diseases	■ **Orelabrutinib** ❑ SLE moving into next stage ❑ Continue patient enrollment for MS	■ **ICP-332** ❑ Initiate Phase II trial in 2022	■ **ICP-488** ❑ IND approved ❑ Initiate Phase I in 2022

Growth Strategies

1. Building a leading hema-oncology franchise with Orelabrutinib & Tafasitamab as backbone therapies
2. Develop Orelabrutinib and other candidates for autoimmune diseases
3. Expand drug portfolio for solid tumors in China and worldwide
4. Establish biological R&D capability through internal and external efforts
5. Continue to expand pipeline through in-house discovery and business development for unmet clinical needs
6. Develop Orelabrutinib in MS through partnership with Biogen
7. Continue to broaden global partnership of internal assets

Financial Update
Key Financials for 2021 Year End

Revenue



Research and Development Costs



Loss for the Period



Cash and Cash Equivalents



[1] Cash balance = investments measured at fair value investments , cash and bank balance
Net cash = cash balance – convertible loan – loans and borrowings – loans from a related party

INNOCARE
诺诚健华

科学驱动创新 患者所需为本

Science Drives Innovation for the Benefit of Patients